controls. Moreover, the role of cMyBP-C as a biomarker in DCM was assessed.
Methodology

Subjects
One hundred and twenty-two patients from the Cardiovascular Department of the First Affiliated Hospital of Nanjing Medical University from August 2016 to October 2017 were selected and enrolled in the study. The 122 subjects consisted of 88 patients with a LVE and 34 normal subjects serving as the control. DCM and hypertension can cause LVE; therefore, the 88 subjects with LVE were further divided into subgroups based on the etiology: either LVEH or DCM, as shown in Figure 1 .
Inclusion criteria for patients with DCM are based on the diagnostic criteria for China's 2007 Cardiomyopathy Diagnosis and Treatment Recommendations: [5] (1) left ventricular end-diastolic diameter (LVDd) >5.0 cm (female) and >5.5 cm (male), (2) 1eft ventricular ejection fraction <45% and/or fractional shortening <25%, and (3) LVDd absolute index value >2.7 cm/m 2 (left end-diastolic diameter absolute index = LVDd (cm) ÷ body surface area (BSA) and BSA (m 2 ) = 0.0061 × height (cm) +0.0128 × body weight [kg]-0.1529). Patients with conditions that can cause myocardial damage such as coronary heart disease, valvular heart disease, congenital heart disease, alcoholic cardiomyopathy, pericardial disease, pulmonary hypertension, and neuromuscular disease were excluded from the study.
Inclusion criteria for patients with left ventricular enlargement due to hypertension is based on the 2010 Guidelines for the Prevention and Treatment of Hypertension in China, [6] that is, in the absence of antihypertensive drugs, blood pressure is measured three times on the same day, systolic blood pressure ≥140 mmHg, and/or diastolic blood pressure ≥90 mmHg. Patients with left ventricular enlargement and currently taking antihypertensive drugs can also be considered. The exclusion criteria were coronary heart disease, diabetes, congenital heart disease, valvular heart disease, pulmonary heart disease, and hyperthyroidism.
A total of 122 patients were enlisted in the study. There were 34 patients in the control group (20 males and 
Data collection
All participants gave informed consent and the hospital's institute committee approved the study protocol.
Gender, age, height, weight, related medical history, biochemical profile, and two-dimensional echocardiography were collected for each patient.
Echocardiography was performed by the Department of Cardiovascular Medicine of the First Affiliated Hospital of Nanjing Medical University with the Vivid E9 ultrasonic apparatus produced by the American EG Company. The parasternal long-axis view was used for echocardiographic measurement of the left ventricular end-diastolic diameter. The left ventricular ejection fraction was averaged over three cardiac cycles.
Specimen collection
All participants underwent a routine blood test after a 12-h fast. 5 ml of blood was collected in a blood tube. After being left for 2 h, it was centrifuged at 3000 rpm for 10 min at 4°C to obtain the upper serum and was collected into a 0.2 ml EP tube and subsequently stored at −80°C.
cMyBP-c content determination Double-antibody sandwich method
The immunologically active cMyBP-C antibody was coated in a 96-well microplate.
As a solid phase carrier, a standard or sample is added to the microplate, wherein cMyBp-C is combined with an antibody attached to the solid support to form an antigen-antibody complex, and then, biotinylated cMyBP-c antibody is added. After washing the unbound biotinylated antibody, Horseradish Peroxidase (HRP)-labeled avidin was added, washed again, and TMB substrate was added for the color development. TMB is converted to a blue color by peroxidase catalysis and eventually converted to yellow under the action of an acid. The color intensity is positively correlated with the amount of cMyBP-C in the sample. The absorbance (Optical Density (OD) value) was measured at 450 nm using a microplate reader to calculate the sample concentration.
Data analysis
After measuring the OD value of each standard, a standard curve was obtained to get the appropriate equation. The content of the sample was then interpolated.
Statistical method
Statistical analysis was performed using the SPSS software version 23.0 (IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp; 2015). Data were expressed as mean ± standard deviation. The comparison between the two groups was analyzed by independent sample t-test; the data of nonnormal distribution were expressed by median and quartile and then converted into normal distribution data for the analysis. The Pearson correlation analysis method was used for the correlation analysis. Statistical significance was defined as P < 0.05.
Results
Serum cMyBP-C content in control group, left ventricular enlargement due to hypertension group, and dilated cardiomyopathy group
There was no significant difference in serum cMyBP-C between the control and the LVEH groups [ Table 1 and Figure 2 ]. The level of cMyBP-c in the DCM group was significantly higher than that in the control and the LVEH groups.
Comparison of clinical data between the control and dilated cardiomyopathy groups
There was no significant difference in gender, age, body mass index, fasting blood glucose, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), and total bilirubin between the control and DCM groups (P > 0.05).
The measured Cr, (Ur, UA, and LVDd levels in the DCM group were significantly higher than those in the controls, and the EF value was significantly lower in patients with DCM [ Table 2 , P < 0.05].
There was no significant correlation between cMyBP-C content and Cr [ Figure 3 ], Ur [ Figure 4 ], UA [ Figure 5 ], EF [ Figure 6 ], and LVDd [ Figure 7 ] in the DCM group [ Table 3 ].
discussion
Myosin Binding Protein-C exists into three isoforms: fast skeletal muscle type (C1), slow skeletal muscle type (C2), and myocardial type (C3). cMyBP-C (C3) is a myocardial-specific protein that is almost exclusively found in cardiomyocytes [7] and has been found to regulate myocardial contraction and relaxation. Contraction and relaxation of the myocardium depend on intact sarcolemma activity and normal coordination of various parts. cMyBP-C is easily soluble and releasable from the sarcomere following cardiac injury. Several reports have confirmed the use of cMyBP-C as a biomarker for myocardial injury. [8, 9] There is a lack of literature regarding the role of cMyBP-C as a biomarker in DCM.
Abnormal levels of cMyBP-C were previously reported in patients with heart failure with or without preserved ejection fraction as compared to controls. [10] Moreover, El Amrousy et al. demonstrated that serum cMyBP-C content in heart failure was significantly higher than the control group, [11] which is consistent with our finding. Several mechanisms could account for an increase in plasma levels of cMyBP-C such as proteolysis and dephosphorylation in the absence of necrosis or apoptosis. [12] The diagnosis of DCM is mainly characterized by left ventricular or bi-ventricular enlargement on echocardiography. However, there are other causes of ventricular enlargement caused by secondary factors. We, therefore, have included a group of patients with left ventricular enlargement due to hypertension (LVEH group) as a subcontrol group for comparison purposes of understanding the correlation between cMyBP-C and left ventricular enlargement due to hypertension. Our study showed no significant difference in serum cMyBP-C between the controls and the hypertensive patients with LVE. However, the serum cMyBP-C levels of DCM patients were significantly higher than both control and LVEH patients, indicating that cMyBP-C release is unlikely to be involved in the pathogenesis of LVE due to hypertension.
There have been numerous reports of the influence of gene mutations expressing cMyBP-C in the development of DCM. Mutations in the gene encoding this protein can lead to a decrease in myocardial contraction and function, but how the structure of the protein or its mechanism of action changes after gene mutation is still unclear.
There is an effort to define the relationship of circulating cMyBP-C in the blood and acute myocardial infarction or heart. In this study, DCM patients were studied against healthy controls, and the ELISA method was used to determine the serum cMyBP-C content. The results were consistent with previously existing reports. The method used to detect circulating cMyBP-C is easy, safe, convenient, and cost-effective. The results of this study may contribute to the use of serum cMyBP-C as a method for risk assessment and clinical diagnosis of DCM in future. At the same time, there were some shortcomings in this study.
First, there was likely recall bias and selection bias, resulting in an inaccurate collection of relevant information. Second, due to limited operating techniques and experimental conditions, systematic errors occur during the detection process. Third, we failed to compare the effect of treatment on the level of circulating cMyBP-C prior and post-therapy. Fourth, several secondary conditions lead to left ventricular enlargement. This study only considered the factor of hypertension. Fifth, we also did not perform coronary angiography to exclude the possibility of coronary heart diseases in the DCM patients. Moreover, we fail to analyse the relationship between cMyBP-c and other biomarkers of heart failure such as BNP or NT-ProBNP. conclusion 1. There was no significant difference in serum cMyBP-C between the control and LVEH groups, suggesting that secondary LVE may have little effect on cMyBP-C release 2. The serum cMyBP-C level in the DCM group was higher than that in control and the hypertensive groups with LVE. The difference was statistically significant, suggesting that there may be changes in the cMyBP-C protein during the development of DCM. cMyBP-C protein has potential to be a new biomarker for the diagnosis of DCM 3. There were significant differences in Cr, Ur, and UA between the DCM group and the normal control group, indicating that the above three factors may be associated with DCM.
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